Short answer
Benitec Biopharma Inc. (BNTC) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$13M
- −44.2% YoY
- EPS (diluted)
- −$0.26
- −18.2% YoY
Source: XBRL data from the Benitec Biopharma Inc. (BNTC) Q3 2026 10-Q on SEC EDGAR. USD.
Benitec Biopharma Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no product sales; no YoY revenue comparison disclosed
- Operating expenses $14.5M vs $9.8M YoY, R&D $8.6M vs $3.4M
- R&D highest growth area, up from $3.4M to $8.6M; G&A $5.9M vs $6.4M
- Cash $176M; operating cash use $3.6M vs $3.4M YoY
- Continued losses expected; cash sufficient for at least twelve months, with clinical-development funding risks
Risk Factors
- No material changes to previously disclosed risk factors in the fiscal 2026 Form 10-K
- Significant carried-forward risks not detailed in this 10-Q section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Benitec Biopharma Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.